Side-by-side comparison
| Property | BPC-157 | TB-500 |
|---|---|---|
| Structure | 15-aa peptide (from gastric-juice protein) | 7-aa fragment of thymosin β4 (Ac-LKKTETQ) |
| Primary mechanism | Angiogenesis via VEGFR2 / growth-factor signaling | Actin binding → cell migration |
| Acts | Locally (and orally on the gut) | Systemically across tissues |
| Plasma half-life | ~15 min (rat; Xu et al. 2022) | Not established — no PK study |
| Biological effect duration | 24–72+ hours (signaling cascade) | Not formally characterized |
| Routes | SC, IM, oral | SC, IM |
| Typical research frequency | Once or twice daily | ~Twice weekly (empirical) |
| Best-discussed use | Tendon/ligament, localized injury, gut | Multi-site / systemic recovery |
| Approval / status | Not approved; WADA-banned | Not approved; WADA-banned |
See the source-level profiles for BPC-157 and TB-500, and our deeper dive on what BPC-157's half-life actually means. You can plot both decay curves with the free half-life calculator.
Mechanism: same goal, different route
BPC-157 — the local repair signal
BPC-157 ("Body Protection Compound") is a stable 15-amino-acid sequence originally isolated from human gastric juice. In animal models it accelerates tissue repair primarily by driving angiogenesis — the growth of new blood vessels — through receptor tyrosine kinase signaling (notably VEGFR2 and downstream Akt). Because much of its action is local, it is typically injected near the target tissue, and its oral stability makes it the logical choice for gut-related applications where the entire GI tract is the target.
TB-500 — the systemic repair signal
TB-500 is a synthetic fragment (amino acids 17–23) of thymosin β4, a 43-amino-acid protein found in nearly every cell. Its active region binds actin and promotes cell migration — recruiting reparative cells to damaged areas. Because it circulates, it does not need to be placed near the injury; a subcutaneous dose can reach multiple sites at once, which is why it is favored for diffuse or multi-joint presentations.
Half-life: where the data thins out
This is the section most pages get wrong. BPC-157's only published pharmacokinetic measurement is a rat study (Xu et al. 2022) reporting a plasma half-life of approximately 15 minutes. TB-500 has no published human or animal PK study — its half-life is an inference from its small size (~796 Da) and lack of any half-life-extending modification, landing somewhere in minutes to a few hours.
Which one — and when
Framed honestly, the injury pattern decides, not preference:
- Localized soft-tissue injury (a single tendon, ligament, or muscle) → BPC-157, injected near the site.
- Gut or GI-tract issues → BPC-157, where oral or systemic dosing reaches the whole target and its evidence is strongest.
- Diffuse, multi-site, or post-surgical presentations → TB-500, because it circulates and reaches several locations.
And in practice many protocols use both — the so-called "Wolverine stack" — pairing BPC-157's local angiogenic repair with TB-500's systemic cell migration. Because the mechanisms are complementary rather than redundant, the combination is the norm rather than an either/or decision. You can map out a combined schedule in the peptide stack planner and handle the dose math in the reconstitution calculator.
Evidence quality and safety
Both compounds share the same fundamental limitation: the efficacy case is built on animal studies. Human data is extremely sparse — the most-cited human report is a small, uncontrolled knee-injection series. Long-term human safety is unknown for either peptide. Reported short-term effects are generally mild (injection-site reactions, transient flushing), but the absence of controlled trials means real risks cannot be ruled out, and product purity in the unregulated market is itself a hazard.
How they fit the wider peptide picture
BPC-157 and TB-500 are the recovery-peptide pair; for the full set of pharmacokinetic profiles across all 44 tracked compounds, see the compound database, and read our methodology for how we grade evidence quality and flag animal-only data.
Frequently asked questions
What is the difference between BPC-157 and TB-500?
BPC-157 promotes angiogenesis and acts locally (and on the gut); TB-500 promotes cell migration and acts systemically. Local repair signal vs systemic repair signal.
Which has a longer half-life?
Both are short in plasma. BPC-157 is ~15 minutes (rat data); TB-500 has no published PK study. BPC-157's biological effects, however, last 24–72+ hours.
Which is better, BPC-157 or TB-500?
Neither universally — the injury type decides, and they are commonly stacked rather than chosen against each other.
Can you stack BPC-157 and TB-500?
Yes; the "Wolverine stack" combines local and systemic repair. No combination protocol has controlled human trial support, and neither is approved.
Are they legal or FDA approved?
No — both are unapproved, in FDA Category 2 (barred from compounding), and on the WADA Prohibited List at all times.
Primary sources and further reading
Effect duration ≠ half-life. Track both.
Halflife plots plasma decay and the longer biological-effect windows for BPC-157, TB-500, and 42 other compounds — overlay the curves, plan the stack, and log injections in one free iOS app.
Download Halflife →